Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2021 May 18

PMID 34003337

Citations 20

Authors

G Hampson

M Stone

J R Lindsay

R K Crowley

S H Ralston

Affiliations

Soon will be listed here.

Abstract

It is acknowledged that the COVID-19 pandemic has caused profound disruption to the delivery of healthcare services globally. This has affected the management of many long-term conditions including osteoporosis as resources are diverted to cover urgent care. Osteoporosis is a public health concern worldwide and treatment is required for the prevention of further bone loss, deterioration of skeletal micro-architecture, and fragility fractures. This review provides information on how the COVID-19 pandemic has impacted the diagnosis and management of osteoporosis. We also provide clinical recommendations on the adaptation of care pathways based on experience from five referral centres to ensure that patients with osteoporosis are still treated and to reduce the risk of fractures both for the individual patient and on a societal basis. We address the use of the FRAX tool for risk stratification and initiation of osteoporosis treatment and discuss the potential adaptations to treatment pathways in view of limitations on the availability of DXA. We focus on the issues surrounding initiation and maintenance of treatment for patients on parenteral therapies such as zoledronate, denosumab, teriparatide, and romosozumab during the pandemic. The design of these innovative care pathways for the management of patients with osteoporosis may also provide a platform for future improvement to osteoporosis services when routine clinical care resumes.

Citing Articles

A case-control study based on the National Health and Nutrition Examination Survey to evaluate the effects of human papilloma virus on bone health in women.

Li X, Jiao G, Chen Y BMC Med. 2025; 23(1):75.

PMID: 39920637 PMC: 11806905. DOI: 10.1186/s12916-025-03909-2.

Correlation of metabolic markers and OPG gene mutations with bone mass abnormalities in postmenopausal women.

Li J, Li Z, Li S, Lu Y, Li Y, Rai P J Orthop Surg Res. 2024; 19(1):706.

PMID: 39487469 PMC: 11529261. DOI: 10.1186/s13018-024-05162-4.

Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019-2023.

Knight K, Fordham R, Crabtree N, Knapp K Osteoporos Int. 2024; 35(8):1451-1460.

PMID: 38795142 DOI: 10.1007/s00198-024-07120-6.

The process of hip fracture management before and during the COVID-19 pandemic in Iran.

Yalamchi F, Khalagi K, Fahimfar N, Tabrizian P, Sanjari M, Mansourzadeh M BMC Geriatr. 2024; 24(1):359.

PMID: 38654154 PMC: 11040962. DOI: 10.1186/s12877-024-04839-z.

Validation of phenomenon and cross-sectional investigation of predictors for a post-COVID-19 surge of osteoporosis outpatients in China.

Sun L, Zhang Y, Chen Y, Chen L, Lei M Sci Rep. 2024; 14(1):4230.

PMID: 38378764 PMC: 10879099. DOI: 10.1038/s41598-024-54858-4.

References

Geusens P, Bours S, Wyers C, van den Bergh J . Fracture liaison programs. Best Pract Res Clin Rheumatol. 2019; 33(2):278-289. DOI: 10.1016/j.berh.2019.03.016. View

Genant H, Jergas M, Palermo L, Nevitt M, Valentin R, Black D . Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996; 11(7):984-96. DOI: 10.1002/jbmr.5650110716. View

Yu E, Tsourdi E, Clarke B, Bauer D, Drake M . Osteoporosis Management in the Era of COVID-19. J Bone Miner Res. 2020; 35(6):1009-1013. PMC: 7273005. DOI: 10.1002/jbmr.4049. View

Tarantino U, Cariati I, Tancredi V, Casamassima D, Piccirilli E, Iundusi R . State of Fragility Fractures Management during the COVID-19 Pandemic. Int J Environ Res Public Health. 2020; 17(21). PMC: 7672624. DOI: 10.3390/ijerph17217732. View

English S, Coyle L, Bradley S, Wilton W, Cordner J, Dempster R . Virtual fracture liaison clinics in the COVID era: an initiative to maintain fracture prevention services during the pandemic associated with positive patient experience. Osteoporos Int. 2021; 32(6):1221-1226. PMC: 7882233. DOI: 10.1007/s00198-021-05882-x. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Clift A, Coupland C, Keogh R, Diaz-Ordaz K, Williamson E, Harrison E . Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020; 371:m3731. PMC: 7574532. DOI: 10.1136/bmj.m3731. View

Palcu P, Munce S, Jaglal S, Allin S, Chishtie J, Silverstein A . Understanding patient experiences and challenges to osteoporosis care delivered virtually by telemedicine: a mixed methods study. Osteoporos Int. 2019; 31(2):351-361. PMC: 7010610. DOI: 10.1007/s00198-019-05182-5. View

Vimaleswaran K, Forouhi N, Khunti K . Vitamin D and covid-19. BMJ. 2021; 372:n544. DOI: 10.1136/bmj.n544. View

10.

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE . Endocr Pract. 2020; 26(5):564-570. DOI: 10.4158/GL-2020-0524. View

11.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

12.

Formenti A, Pedone E, Di Filippo L, Ulivieri F, Giustina A . Are women with osteoporosis treated with denosumab at risk of severe COVID-19?. Endocrine. 2020; 70(2):203-205. PMC: 7502215. DOI: 10.1007/s12020-020-02500-4. View

13.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guanabens N . Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017; 105:11-17. DOI: 10.1016/j.bone.2017.08.003. View

14.

Arafa M, Nesar S, Abu-Jabeh H, Jayme M, Kalairajah Y . COVID-19 pandemic and hip fractures: impact and lessons learned. Bone Jt Open. 2020; 1(9):530-540. PMC: 7659637. DOI: 10.1302/2633-1462.19.BJO-2020-0116.R1. View

15.

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

16.

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

17.

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

18.

Thevarajan I, Nguyen T, Koutsakos M, Druce J, Caly L, van de Sandt C . Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; 26(4):453-455. PMC: 7095036. DOI: 10.1038/s41591-020-0819-2. View

19.

McLellan A, Gallacher S, Fraser M, McQuillian C . The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003; 14(12):1028-34. DOI: 10.1007/s00198-003-1507-z. View

20.

Kirwan R, McCullough D, Butler T, Perez de Heredia F, Davies I, Stewart C . Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss. Geroscience. 2020; 42(6):1547-1578. PMC: 7528158. DOI: 10.1007/s11357-020-00272-3. View